JP4920134B2
(ja)
*
|
1999-05-07 |
2012-04-18 |
ジョンズ ホプキンス ユニヴァーシティ スクール オヴ メディシン |
眼障害の処置におけるプロテインチロシンキナーゼ経路インヒビターの使用
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
WO2001057020A1
(en)
*
|
2000-02-01 |
2001-08-09 |
Cor Therapeutics, Inc. |
INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
|
JP2001302667A
(ja)
|
2000-04-28 |
2001-10-31 |
Bayer Ag |
イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
|
IL156306A0
(en)
|
2000-12-21 |
2004-01-04 |
Glaxo Group Ltd |
Pyrimidineamines as angiogenesis modulators
|
HUP0302525A2
(hu)
|
2001-01-05 |
2003-10-28 |
Abgenix, Inc. |
Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
|
RU2259825C9
(ru)
|
2001-06-18 |
2006-04-10 |
БиоДием Лимитед |
Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US7622479B2
(en)
*
|
2001-11-26 |
2009-11-24 |
Takeda Pharmaceutical Company Limited |
Bicyclic derivative, its production and use
|
JP2005527511A
(ja)
|
2002-03-01 |
2005-09-15 |
ファイザー インコーポレイテッド |
抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
|
CN101597262A
(zh)
*
|
2002-03-05 |
2009-12-09 |
特兰斯泰克制药公司 |
抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
PA8580301A1
(es)
|
2002-08-28 |
2005-05-24 |
Pfizer Prod Inc |
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
|
EP1565187A4
(de)
|
2002-11-13 |
2010-02-17 |
Novartis Vaccines & Diagnostic |
Verfahren zur behandlung von krebs undverwandte verfahren
|
PT1585743E
(pt)
|
2002-12-19 |
2007-07-12 |
Pfizer |
Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
|
ES2401330T3
(es)
|
2003-02-26 |
2013-04-18 |
Sugen, Inc. |
Compuesto de heteroarilamino inhibidores de proteín quinasas
|
BRPI0413876A
(pt)
|
2003-08-29 |
2006-10-24 |
Pfizer |
tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
BRPI0418102A
(pt)
|
2003-12-23 |
2007-04-27 |
Pfizer |
derivados de quinolina
|
WO2005075470A1
(en)
|
2004-01-28 |
2005-08-18 |
Smithkline Beecham Corporation |
Thiazole compounds
|
CA2556872C
(en)
|
2004-02-20 |
2015-05-12 |
Chiron Corporation |
Modulation of inflammatory and metastatic processes
|
AU2005250116B2
(en)
|
2004-06-01 |
2011-01-20 |
F. Hoffmann-La Roche Ag |
3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
|
WO2006009734A1
(en)
|
2004-06-17 |
2006-01-26 |
Wyeth |
Gonadotropin releasing hormone receptor antagonists
|
US7714130B2
(en)
|
2004-06-17 |
2010-05-11 |
Wyeth |
Processes for preparing gonadotropin releasing hormone receptor antagonists
|
BRPI0513915A
(pt)
|
2004-08-26 |
2008-05-20 |
Pfizer |
compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
JP4324636B2
(ja)
|
2005-03-31 |
2009-09-02 |
アジェンシス,インコーポレイテッド |
161p2f10bタンパク質に結合する抗体および関連分子
|
AP2552A
(en)
|
2005-04-26 |
2013-01-08 |
Pfizer |
P-cadherin antibodies
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
KR101368519B1
(ko)
|
2005-05-23 |
2014-02-27 |
노파르티스 아게 |
결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
PL2960253T3
(pl)
|
2005-09-07 |
2018-11-30 |
Amgen Fremont Inc. |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
EP1957488B1
(de)
|
2005-11-30 |
2009-09-09 |
F.Hoffmann-La Roche Ag |
3-amino-2-arylpropylazaindole und anwendungen davon
|
BRPI0619247A2
(pt)
|
2005-11-30 |
2011-09-20 |
Hoffmann La Roche |
métodos para a sìntese de 3-amino-1-aril-propila indóis
|
BRPI0619263A2
(pt)
|
2005-11-30 |
2011-09-27 |
Hoffmann La Roche |
indóis de 3-amino-1-arilpropila e indóis aza-substituìdos, métodos para prepará-los, composição farmacêutica e uso dos referidos indóis
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
WO2007132307A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
ES2424745T3
(es)
|
2007-09-07 |
2013-10-08 |
Agensys, Inc. |
Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12
|
CN101801951B
(zh)
|
2007-09-14 |
2013-11-13 |
杨森制药有限公司 |
1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
|
RU2510396C2
(ru)
|
2008-09-02 |
2014-03-27 |
Янссен Фармасьютикалз, Инк. |
3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
|
WO2010030360A1
(en)
*
|
2008-09-11 |
2010-03-18 |
Arena Pharmaceuticals, Inc. |
3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
AU2009319387B2
(en)
|
2008-11-28 |
2012-05-10 |
Addex Pharma S.A. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
CA2748943A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
RS53075B
(en)
|
2009-05-12 |
2014-04-30 |
Janssen Pharmaceuticals Inc. |
1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
JP5707390B2
(ja)
|
2009-05-12 |
2015-04-30 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド |
1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
|
MX2012000620A
(es)
|
2009-07-13 |
2012-01-27 |
Genentech Inc |
Metodos diagnostico y composiciones para tratamiento de cancer.
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
CN102597776A
(zh)
|
2009-09-11 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌剂的可能性升高的患者的方法
|
US20110064732A1
(en)
|
2009-09-17 |
2011-03-17 |
Sanne Lysbet De Haas |
Methods and compositions for diagnostic use in cancer patients
|
TWI517850B
(zh)
|
2009-09-30 |
2016-01-21 |
Vtv治療有限責任公司 |
經取代之咪唑衍生物及其使用方法
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
DK3150610T3
(da)
|
2010-02-12 |
2019-11-04 |
Pfizer |
Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
|
EP2519826A2
(de)
|
2010-03-03 |
2012-11-07 |
OSI Pharmaceuticals, LLC |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
CA2802857C
(en)
|
2010-06-16 |
2018-09-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012010551A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
CA2806921C
(en)
|
2010-07-23 |
2019-11-26 |
Trustees Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
EP2661435B1
(de)
|
2010-11-08 |
2015-08-19 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
|
EP2649069B1
(de)
|
2010-11-08 |
2015-08-26 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
|
EP2643320B1
(de)
|
2010-11-08 |
2015-03-04 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
WO2012145183A2
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
ES2834093T3
(es)
|
2011-07-21 |
2021-06-16 |
Sumitomo Dainippon Pharma Oncology Inc |
Inhibidores de proteína quinasa heterocíclicos
|
JP5914667B2
(ja)
|
2011-09-22 |
2016-05-11 |
ファイザー・インク |
ピロロピリミジンおよびプリン誘導体
|
CA2848842C
(en)
|
2011-10-04 |
2020-09-29 |
King's College London |
Ige anti -hmw-maa antibody
|
CN104271599A
(zh)
|
2011-11-08 |
2015-01-07 |
辉瑞公司 |
使用抗m-csf抗体治疗炎性疾病的方法
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
KR101738063B1
(ko)
|
2012-09-21 |
2017-05-19 |
아로그 파마슈티칼스, 인코퍼레이티드 |
구조적으로 활성인 인산화된 flt3 키나제의 억제 방법
|
US11642340B2
(en)
|
2012-09-26 |
2023-05-09 |
Arog Pharmaceuticals, Inc. |
Method of inhibiting mutant C-KIT
|
US10835525B2
(en)
|
2012-09-26 |
2020-11-17 |
Arog Pharmaceuticals, Inc. |
Method of inhibiting mutant C-KIT
|
JP6042157B2
(ja)
|
2012-09-26 |
2016-12-14 |
アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーArog Pharmaceuticals,LLC |
変異型c−kitの阻害方法
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
ES2860298T3
(es)
|
2014-01-21 |
2021-10-04 |
Janssen Pharmaceutica Nv |
Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
|
DK3431106T3
(da)
|
2014-01-21 |
2021-03-15 |
Janssen Pharmaceutica Nv |
Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
|
CN106460060B
(zh)
|
2014-04-04 |
2020-02-11 |
中美冠科生物技术(太仓)有限公司 |
Hnf4g-rspo2融合基因及其在癌症治疗中的用途
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
BR112016024513A2
(pt)
|
2014-04-30 |
2017-08-15 |
Pfizer |
derivados de di-heterociclo ligados à cicloalquila
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
MX2017013956A
(es)
|
2015-05-01 |
2018-09-05 |
Cocrystal Pharma Inc |
Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
|
US9758539B2
(en)
|
2015-05-18 |
2017-09-12 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
CN108289861B
(zh)
|
2015-08-03 |
2021-11-02 |
大日本住友制药肿瘤公司 |
用于治疗癌症的组合疗法
|
CA2997556C
(en)
*
|
2015-09-03 |
2020-12-22 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of dyrk1a and uses thereof
|
CA3006743A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
CA3024012A1
(en)
|
2016-11-02 |
2018-05-11 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating flt3 mutated proliferative disorders associated mutations
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018119000A1
(en)
|
2016-12-19 |
2018-06-28 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
CN110840893A
(zh)
|
2018-12-13 |
2020-02-28 |
安罗格制药有限责任公司 |
含克莱拉尼的药物组合物及其用途
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
US11465998B2
(en)
|
2019-04-25 |
2022-10-11 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods of use thereof
|
US11471451B2
(en)
|
2019-08-19 |
2022-10-18 |
Arog Pharmaceuticals, Inc. |
Uses of crenolanib
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
US11524006B2
(en)
|
2020-09-17 |
2022-12-13 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating TRK kinase associated proliferative disorders
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
JP2023063189A
(ja)
|
2021-10-22 |
2023-05-09 |
アログ・ファーマシューティカルズ・インコーポレイテッド |
以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ
|